Macrophage activation markers are associated with infection and mortality in patients with acute liver failure.
acute liver failure
innate immunity
macrophages
organ failure
sepsis
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
revised:
18
03
2024
received:
03
11
2023
accepted:
21
03
2024
medline:
8
4
2024
pubmed:
8
4
2024
entrez:
8
4
2024
Statut:
aheadofprint
Résumé
Acute liver failure is a multisystem disorder with a high mortality and frequent need for emergency liver transplantation. Following massive innate immune system activation, soluble markers of macrophage activation are released during liver damage and their association with disease severity and prognosis requires exploration. Patients ALF from the United States Acute Liver Failure Study Group (USALFSG, n = 224) and King's College Hospital (n = 40) together with healthy controls (HC, n = 50) were recruited. Serum from early (Days 1-3) and late (>Day 3) time points were analysed for MAMs by enzyme-linked immunosorbent assay correlated to markers of illness severity and 21-day spontaneous survival. Surface expression phenotyping was performed via Flow Cytometry on CD14 All MAMs serum concentrations were significantly higher in ALF compared to controls (p < .0001). sCD206 concentration was higher in early and late stages of the disease in patients with bacteraemia (p = .002) and infection in general (p = .006). In MELD-adjusted multivariate modelling, sCD206 and sCD163 were independently associated with mortality. CD14 sCD206 is increased in serum of ALF patients with infections and poor outcome and is upregulated on CD14
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Acute liver failure is a multisystem disorder with a high mortality and frequent need for emergency liver transplantation. Following massive innate immune system activation, soluble markers of macrophage activation are released during liver damage and their association with disease severity and prognosis requires exploration.
METHODS
METHODS
Patients ALF from the United States Acute Liver Failure Study Group (USALFSG, n = 224) and King's College Hospital (n = 40) together with healthy controls (HC, n = 50) were recruited. Serum from early (Days 1-3) and late (>Day 3) time points were analysed for MAMs by enzyme-linked immunosorbent assay correlated to markers of illness severity and 21-day spontaneous survival. Surface expression phenotyping was performed via Flow Cytometry on CD14
RESULTS
RESULTS
All MAMs serum concentrations were significantly higher in ALF compared to controls (p < .0001). sCD206 concentration was higher in early and late stages of the disease in patients with bacteraemia (p = .002) and infection in general (p = .006). In MELD-adjusted multivariate modelling, sCD206 and sCD163 were independently associated with mortality. CD14
CONCLUSIONS
CONCLUSIONS
sCD206 is increased in serum of ALF patients with infections and poor outcome and is upregulated on CD14
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2024 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525‐2534.
Rolando N, Philpott‐Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16(4):389‐402.
Karvellas CJ, Pink F, McPhail M, et al. Predictors of bacteraemia and mortality in patients with acute liver failure. Intensive Care Med. 2009;35(8):1390‐1396.
Triantafyllou E, Woollard KJ, McPhail MJW, Antoniades CG, Possamai LA. The role of monocytes and macrophages in acute and acute‐on‐chronic liver failure. Front Immunol. 2018;9:2948.
Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13(3):267‐276.
Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008;49(5):845‐861.
Nielsen MC, Hvidbjerg Gantzel R, Claria J, Trebicka J, Moller HJ, Gronbaek H. Macrophage activation markers, CD163 and CD206, in acute‐on‐chronic liver failure. Cells. 2020;9(5):1175‐1193.
Antoniades CG, Khamri W, Abeles RD, et al. Secretory leukocyte protease inhibitor: a pivotal mediator of anti‐inflammatory responses in acetaminophen‐induced acute liver failure. Hepatology. 2014;59(4):1564‐1576.
Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol. 2005;40(1):52‐56.
Moller HJ, Gronbaek H, Schiodt FV, et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol. 2007;47(5):671‐676.
Triantafyllou E, Pop OT, Possamai LA, et al. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. Gut. 2018;67(2):333‐347.
Zhu X, Lang J. Soluble PD‐1 and PD‐L1: predictive and prognostic significance in cancer. Oncotarget. 2017;8(57):97671‐97682.
Triantafyllou E, Gudd CL, Mawhin MA, et al. PD‐1 blockade improves Kupffer cell bacterial clearance in acute liver injury. J Clin Invest. 2021;131(4):e140196.
Gronbaek H, Gantzel RH, Laursen TL, Kazankov K, Moller HJ. Macrophage markers and innate immunity in cirrhosis. J Hepatol. 2020;73(6):1586‐1588.
Iida T, Wagatsuma K, Hirayama D, Nakase H. Is Osteopontin a friend or foe of cell apoptosis in inflammatory gastrointestinal and liver diseases? Int J Mol Sci. 2017;19(1):7‐22.
Bruha R, Vitek L, Smid V. Osteopontin—a potential biomarker of advanced liver disease. Ann Hepatol. 2020;19(4):344‐352.
Zhang Y, Xiao N, Liu Q, Nie Y, Zhu X. Increased serum levels of sCD206 are associated with adverse prognosis in patients with HBV‐related decompensated cirrhosis. Dis Markers. 2022;2022:7881478.
Tsuchiya K, Suzuki Y, Yoshimura K, et al. Macrophage mannose receptor CD206 predicts prognosis in community‐acquired pneumonia. Sci Rep. 2019;9(1):18750.
McPhail MJ, Farne H, Senvar N, Wendon JA, Bernal W. Ability of King's college criteria and model for end‐stage liver disease scores to predict mortality of patients with acute liver failure: a meta‐analysis. Clin Gastroenterol Hepatol. 2016;14(4):516‐525.
Karvellas CJ, Pink F, McPhail M, et al. Bacteremia, acute physiology and chronic health evaluation II and modified end stage liver disease are independent predictors of mortality in critically ill nontransplanted patients with acute on chronic liver failure. Crit Care Med. 2010;38(1):121‐126.
Nielsen MC, Andersen MN, Rittig N, et al. The macrophage‐related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. J Leukoc Biol. 2019;106(5):1129‐1138.
Bernsmeier C, Pop OT, Singanayagam A, et al. Patients with acute‐on‐chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology. 2015;148(3):603‐615 e614.
Trovato FM, Zia R, Artru F, et al. Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure. J Hepatol. 2023;78(3):558‐573.
Sandahl TD, McGrail R, Moller HJ, et al. The macrophage activation marker sCD163 combined with markers of the enhanced liver fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis. Aliment Pharmacol Ther. 2016;43(11):1222‐1231.
Gronbaek H, Sandahl TD, Mortensen C, Vilstrup H, Moller HJ, Moller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther. 2012;36(2):173‐180.
Holland‐Fischer P, Gronbaek H, Sandahl TD, et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut. 2011;60(10):1389‐1393.
Siggaard CB, Kazankov K, Rodgaard‐Hansen S, et al. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose. Scand J Gastroenterol. 2019;54(5):623‐632.
Saha B, Tornai D, Kodys K, et al. Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis. Hepatology. 2019;70(4):1134‐1149.
Tavabie OD, Karvellas CJ, Salehi S, et al. A novel microRNA‐based prognostic model outperforms standard prognostic models in patients with acetaminophen‐induced acute liver failure. J Hepatol. 2021;75(2):424‐434.